

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Rankin Aubrey</u> (Last) (First) (Middle) C/O REVANCE THERAPEUTICS, INC 1222 DEMONBREUN STREET, SUITE 2000 (Street) NASHVILLE TN 37203 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Revance Therapeutics, Inc. [RVNC]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>President, Innovation & Tech</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/15/2021</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/15/2021		F		4,949 ⁽¹⁾	D	\$26.02 ⁽²⁾	74,827	D	
Common Stock	08/16/2021		s ⁽³⁾		9,364	D	\$26.3412 ⁽⁴⁾	65,463	D	
Common Stock								321,611	I	Aubrey and Luanne Rankin Revocable Living Trust Dated July 1, 2009 ⁽⁵⁾
Common Stock								154,302	I	The Rankin Irrevocable Trust ⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Explanation of Responses:

- Represents the number of shares withheld by and surrendered to the Issuer on August 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 57,251 shares. The RSA vests in three equal annual installments from August 15, 2020, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Inducement Plan (the "Plan")) on each vesting date.
- The fair market value was determined on August 13, 2021 pursuant to the Plan.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Rankin.
- The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$25.67 to \$26.71. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
- These shares are held by The Rankin Irrevocable Trust, of which the children of Mr. Rankin are beneficiaries.

Remarks:

/s/ Dwight Moxie, Attorney-in-Fact 08/17/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

